

9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982

Email: info@abeomics.com

## 12-4026: Phospho-PLCg2 (Tyr759) (Clone: G3) rabbit mAb PE conjugate

Clonality: Monoclonal
Clone Name: PLCG2Y759-G3

**Application:** FACS

**Reactivity:** Human, Mouse

Conjugate: PE

Format: Conjugated

Alternative Name:

1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2, Phosphoinositide

phospholipase C-gamma-2, PLC-IV, PLC-gamma-2, PLCG2

**Isotype:** Rabbit IgG1k

Immunogen Information: A synthetic phospho-peptide corresponding to residues surrounding Tyr759 of human

phospho PLCg2.

## **Description**

The PLC-gamma isoforms of the PI-PLC family of lipases are regulated by growth factor receptors and B- and T-cell antigen receptors. While PLCg1 is expressed ubiquitously, PLCg2 is predominantly expressed in liver cells. PLCg2 plays a dominant role in B-cell signaling. Btk directly phosphorylates PLCg2, though the Syk kinase and BLNK adaptor protein are required. Both Tyr753 and Tyr759 have been identified as important phosphorylation sites for PLCg2 activation in B-cells. PLCg2 missense mutations and genomic deletions have been identified autoinflammatory diseases in humans. These include gain-of-function mutations, such as S707T, that possibly introduce an additional phosphorylation site and increase basal PLCg2 activity.

## **Product Info**

Amount: 10 Tests / 100 Tests

**Content:** 1X PBS, 0.09% NaN3, 0.2% BSA

**Storage condition :** Store at 2-8°C. Avoid repeated freeze and thaw cycles.

## **Application Note**

For flow cytometric staining, the suggested use of this reagent is  $5 \text{ A} \square \text{A} \mu \text{L}$  per million cells or  $5 \text{ A} \square \text{A} \mu \text{L}$  per 100  $\text{A} \square \text{A} \mu \text{L}$  of staining volume. It is recommended that the reagent be titrated for optimal performance for each application.




Fig-1: Flow cytometric analysis of Ramos cells unstained treated with imatinib (blue) or stained and treated with imatinib (red) or treated with pervanadate (green) using phospho-PLCg2 (Tyr759) antibody PLCG2Y759-G3 PE conjugate.